You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
|
---|---|
Published in |
Clinical Cancer Research, July 2015
|
DOI | 10.1158/1078-0432.ccr-15-0363 |
Pubmed ID | |
Authors |
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, Jennifer A. Wargo |
Abstract |
BRAF inhibitor treatment (BRAFi) enhances anti-tumor immunity, but is associated with increased intra-tumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function, however recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Ecuador | 1 | 2% |
Unknown | 40 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 13 | 31% |
Student > Ph. D. Student | 7 | 17% |
Other | 6 | 14% |
Student > Bachelor | 2 | 5% |
Student > Master | 2 | 5% |
Other | 2 | 5% |
Unknown | 10 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 21% |
Biochemistry, Genetics and Molecular Biology | 8 | 19% |
Agricultural and Biological Sciences | 4 | 10% |
Immunology and Microbiology | 3 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Other | 4 | 10% |
Unknown | 12 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2015.
All research outputs
#16,122,040
of 23,923,788 outputs
Outputs from Clinical Cancer Research
#10,742
of 12,844 outputs
Outputs of similar age
#157,056
of 265,662 outputs
Outputs of similar age from Clinical Cancer Research
#130
of 175 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,844 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,662 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 175 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.